BioPredia BioTech Co., Ltd founded on December 26, 2014, is located at NO.51, the fourth phase of China Pharmaceutical City, Taizhou, Jiangsu Province. The company was founded by a team of experts who have been engaged in the research and development, production and quality management of in vitro diagnostic reagent products for a long time at home and abroad. The registered capital of the company is RMB 13,636,400. It has a wholly-owned subsidiary, Nanjing BioPredia Medicine Co., Ltd., which is located in room 2102-2104, block B, phase I, Zhongdan Ecological Life Science Industrial Park, No. 3-1, xinjinhu Road, Nanjing high tech Development Zone.
BioPredia BioTech Co., Ltd is committed to the research, production and technology promotion and application of the world's top diagnostic technology, xMAP liquid-phase chip technology (also known as flow fluorescence technology), so that more people can enjoy the benefits brought by high-tech to health. Liquid chip technology is advanced in the field of immunodiagnosis: sensitivity, accuracy, specificity and reproducibility, high detection efficiency, low sample consumption and low cost, which is especially suitable for early diagnosis of complex diseases with large sample size and high throughput nucleic acid detection. Frost & Sullivan an authority on the global technology industry and industry research, awarded liquid-phase chip technology the " International Clinical Diagnostic Technology innovation award 2005".Promulgated by the State Council in 2016 much starker choices-and graver consequences-in national science and technology innovation plan and released in 2017, the Ministry of science and Technology issued the 13th five year plan for medical device innovation, listing the liquid-phase suspension chips as "major products to be developed" and "cutting-edge technologies to speed up development", and from the level of national science and technology development strategy, liquid-phase chip technology was put forward. The importance of technology has been raised to a new height, which has attracted the attention of the same industry and entered the bureau one after another. The company has been favored by the same industry and investment institutions in the early stage of its development. In 2017, it obtained tens of millions of yuan equity investment from Hangzhou Chende and Guangzhou Jinyuan (invested and managed by Guangzhou Jinyu inspection group), which has injected vitality into the company's development.
The company has profound technical strength, and its founders have worked in Bio-Rad,Merck Millipore,Myriad Genetics-RBM and other world-famous biological companies are engaged in research, development and production management of liquid-phase chip technology and products. They have accumulated rich experience in the development and verification of liquid-phase chip joint inspection kit, detection system and microsphere. The R&D team has strong technical strength, and the product process is mature and stable. The sound management system of production and quality lays a solid foundation for the healthy and rapid development of the company. The products developed by the company include: gonadal and thyroid hormones, tumor markers, autoimmune diseases, Alzheimer's disease, car-t immunotherapy safety monitoring, allergens, cytokines and other series of multiple detection kits for clinical diagnosis, as well as automatic high-throughput liquid chip detection system.
